Summary

This article discusses results from the Determining the Efficacy and Tolerability of CETP Inhibition with Anacetrapib [DEFINE; NCT00685776] trial, which showed that anacetrapib safely and substantially lowered LDL-C and raised HDL-C levels in patients with coronary heart disease.